Peripheral arterial disease (PAD) occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and life-threatening non-healing leg ulcers. According to the American Heart Association, this condition affects approximately 8 to 12 million Americans. With only about 25 percent of PAD patients undergoing treatment, it is a disease that is largely under-diagnosed and under-treated. If left untreated, PAD can lead to critical leg ischemia, a condition where not enough blood is being delivered to the leg to keep the tissue alive. Total loss of circulation to the legs and feet can cause gangrene and lead to amputation.
Avinger, Inc. and PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of a structured financing and royalty transaction on April 18, 2013, in which PDL will provide Avinger with up to $40 million of mezzanine financing.
Although chelation therapy with the drug disodium EDTA has been used for many years with limited evidence of efficacy for the treatment of coronary disease, a randomized trial that included patients with a prior heart attack found that use of a chelation regimen modestly reduced the risk of a composite of adverse cardiovascular outcomes.
Among adults without diabetes, quitting smoking, compared with continuing smoking, was associated with a lower risk of cardiovascular disease despite subsequent weight gain, according to a study appearing in the March 13 issue of JAMA.
Using the higher of left and right arm single blood pressure readings taken sequentially leads to an overestimation of patients’ “true” level as determined by ambulatory monitoring, UK researchers warn.
Using the higher of left and right arm single blood pressure readings taken sequentially leads to an overestimation of patients’ “true” level as determined by ambulatory monitoring, UK researchers warn.
Six months of treatment with the angiotensin-converting enzyme inhibitor ramipril produces notable improvements in the walking ability of patients with peripheral artery disease and intermittent claudication, shows a large randomized trial.
Among patients with peripheral artery disease and intermittent claudication (pain in the calf that comes and goes, typically felt while walking), 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor ramipril was associated with improvement in pain-free and maximum walking times and the physical health aspect of quality of life, according to a study appearing in the February 6 issue of JAMA.
AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the launch of its new 100 mm length AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD) below the knee (BTK).
In our particular study we used a survey which consisted of 50 different questions which get at different aspects of sleep health. It was a patient self-report.
Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).
Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale.
The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked as a result of peripheral artery disease (PAD).
Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for crossing chronic total occlusions (CTOs) in patients with Peripheral Artery Disease (PAD), announces its Ocelot System has been cleared for sale in the U.S. by the Food and Drug Administration (FDA).
Smoking, Type 2 diabetes, hypertension, and hypercholesterolemia are significantly associated with the risk for clinically significant peripheral artery disease in men, with each additional factor doubling the risk, conclude US and Dutch researchers.
Smoking, Type 2 diabetes, hypertension, and hypercholesterolemia are significantly associated with the risk for clinically significant peripheral artery disease in men, with each additional factor doubling the risk, conclude US and Dutch researchers.
Among nearly 45,000 men who were followed up for more than two decades, those with the risk factors of smoking, hypertension, high cholesterol, and type 2 diabetes had an associated greater risk of developing PAD, according to a study in the October 24/31 issue of JAMA.
Use of balloon angioplasty and placement of stents to widen clogged arteries have become standard medical procedure. Further advancing this treatment, drug-eluting devices are now delivering medication directly to the site where it can be most effective. While this technique has met with success in coronary arteries, its use in peripheral arteries is still under study.
Among patients with diabetes and comorbid depression, the time point at which they developed depression may have important implications for their clinical management, say researchers.
Depression was linked with an increased risk of peripheral artery disease (PAD) in a study of more than one thousand men and women with heart disease conducted by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.
Cardionovum GmbH announced today that it expects to launch in Europe in Q4 2012 a next-generation Sirolimus-eluting coronary stent system—PROLIMUS Biograde—which is designed to optimize long-term patient results. Unlike many state-of-the-art DES that are currently being marketed, PROLIMUS Biograde provides multiple pro-healing product features to promote early re-endothelialization.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.